Oryzon to invest eur 20 million to develop new drugs

Biotech company oryzon genomics has announced a four-year program to invest eur 20 million in the development of new drugs. oryzon ceo carlos buesa indicated that the company would use the resources to strengthen its research on biomarkers and antibody therapy.

oryzon recently opened its new 2,300-square-meter corporate headquarters in cornellà de llobregat (barcelona), with an investment of eur 2.5 million. the company expects revenue of eur 8 million for its current fiscal year.

source: expansión catalunya, 08/09/09